Earnings Call Summary | Allurion Technologies(ALUR.US) Q1 2024 Earnings Conference
Earnings Call Summary | Allurion Technologies(ALUR.US) Q1 2024 Earnings Conference
The following is a summary of the Allurion Technologies Inc. (ALUR) Q1 2024 Earnings Call Transcript:
以下是Allurion Technologies Inc.（ALUR）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Allurion Technologies reported a Q1 2024 revenue of $9.4 million, reflecting a 14% increase from Q4 2023 but a 33% decrease from Q1 2023.
The company witnessed an increase in gross margins to 73% for the quarter compared to last year's 39%, attributed to reduced manufacturing labor and overhead costs due to lower production volumes temporarily.
Cash and cash equivalents at the end of Q1 2024 were $29.7 million, a decrease of $8.4 million from December 31, 2023.
Cash burn reduced by 62% compared to Q4 2023, primarily due to strategic spending cuts.
Allurion Technologies報告稱，2024年第一季度收入爲940萬美元，較2023年第四季度增長了14％，但比2023年第一季度下降了33％。
該公司本季度的毛利率從去年的39％增長到73％，這要歸因於產量暫時減少導致製造勞動力和管理費用減少。
截至2024年第一季度末，現金及現金等價物爲2970萬美元，較2023年12月31日減少840萬美元。
與2023年第四季度相比，現金消耗減少了62％，這主要是由於戰略支出削減。
Business Progress:
業務進展：
The company reported a 22% increase in procedural volumes as indicated by new app users compared to Q4 2023 and 12% compared to Q1 2023.
The announced partnership with the UK's National Health Service (NHS) highlights potential for significant growth and expected future reimbursement opportunities.
In January 2024, Allurion showcased its impressive weight loss program's results in improving obesity-related comorbidities.
The launch of 'Virtual Care Suite' for US healthcare providers indicates the company's move towards facilitating remote patient monitoring and telehealth services.
該公司報告稱，與2023年第四季度相比，新應用程序用戶的程序量增長了22％，與2023年第一季度相比增長了12％。
宣佈的與英國國家衛生服務局（NHS）的合作伙伴關係凸顯了顯著增長的潛力和預期的未來報銷機會。
2024年1月，Allurion展示了其令人印象深刻的減肥計劃在改善肥胖相關合並症方面的成果。
針對美國醫療保健提供商的 “虛擬護理套件” 的推出表明該公司正朝着促進遠程患者監測和遠程醫療服務邁進。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。